CYLD

Summary

Gene Symbol: CYLD
Description: CYLD lysine 63 deubiquitinase
Alias: BRSS, CDMT, CYLD1, CYLDI, EAC, MFT, MFT1, SBS, TEM, USPL2, ubiquitin carboxyl-terminal hydrolase CYLD, cylindromatosis (turban tumor syndrome), deubiquitinating enzyme CYLD, ubiquitin specific peptidase like 2, ubiquitin thioesterase CYLD, ubiquitin thiolesterase CYLD, ubiquitin-specific-processing protease CYLD
Species: human
Products:     CYLD

Top Publications

  1. Biggs P, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y, et al. Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet. 1995;11:441-3 pubmed
    ..Using markers close to the cylindromatosis gene, consistent loss of the wild-type allele was observed in 19 tumours from four individuals in the two families, indicating that the gene is likely to be a tumour suppressor gene. ..
  2. Thomson S, Rasmussen S, Zhang J, Wallace M. A new hereditary cylindromatosis family associated with CYLD1 on chromosome 16. Hum Genet. 1999;105:171-3 pubmed
    ..Previously, the HC gene (CYLD1) was linked to chromosome 16q12-13, and tumors showed loss of heterozygosity (LOH), suggesting that CYLD1 is a ..
  3. Sun L, Gao J, Huo L, Sun X, Shi X, Liu M, et al. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. J Pathol. 2010;221:425-32 pubmed publisher
    The familial cylindromatosis tumour suppressor CYLD contains three cytoskeleton-associated protein glycine-rich (CAP-Gly) domains and a deubiquitinase domain...
  4. Jenner M, Leone P, Walker B, Ross F, Johnson D, Gonzalez D, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110:3291-300 pubmed
    ..loss of heterozygosity (LOH) involving 3 regions: the whole of 16q, a region centered on 16q12 (the location of CYLD), and a region centered on 16q23 (the location of the WW domain-containing oxidoreductase gene WWOX)...
  5. Alameda J, Moreno Maldonado R, Navarro M, Bravo A, Ramirez A, Page A, et al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene. 2010;29:6522-32 pubmed publisher
    In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD(C/S)) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD ..
  6. Komatsu K, Lee J, Miyata M, Hyang Lim J, Jono H, Koga T, et al. Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun. 2013;4:1684 pubmed publisher
    The deubiquitinase CYLD acts as a key negative regulator to tightly control overactive inflammation...
  7. O Donnell M, Perez Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol. 2011;13:1437-42 pubmed publisher
    ..We now identify CYLD as a substrate for caspase 8 that satisfies these criteria...
  8. Lim J, Jono H, Komatsu K, Woo C, Lee J, Miyata M, et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun. 2012;3:771 pubmed publisher
    ..Here we show that loss of deubiquitinase CYLD led to the development of lung fibrosis in mice after infection with Streptococcus pneumoniae...
  9. Wang L, Baiocchi R, Pal S, Mosialos G, Caligiuri M, SIF S. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol. 2005;25:7953-65 pubmed
    ..was associated with up-regulation of proapoptotic genes including the tumor suppressor familial cylindromatosis (CYLD), which was found to be a direct target of BAF57 as determined by chromatin immunoprecipitation analysis...
  10. Yoshida H, Jono H, Kai H, Li J. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem. 2005;280:41111-21 pubmed
    ..provided direct evidence for the negative regulation of TLR2 signaling by the tumor suppressor cylindromatosis (CYLD)...

Detail Information

Publications62

  1. Biggs P, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y, et al. Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet. 1995;11:441-3 pubmed
    ..Using markers close to the cylindromatosis gene, consistent loss of the wild-type allele was observed in 19 tumours from four individuals in the two families, indicating that the gene is likely to be a tumour suppressor gene. ..
  2. Thomson S, Rasmussen S, Zhang J, Wallace M. A new hereditary cylindromatosis family associated with CYLD1 on chromosome 16. Hum Genet. 1999;105:171-3 pubmed
    ..Previously, the HC gene (CYLD1) was linked to chromosome 16q12-13, and tumors showed loss of heterozygosity (LOH), suggesting that CYLD1 is a ..
  3. Sun L, Gao J, Huo L, Sun X, Shi X, Liu M, et al. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. J Pathol. 2010;221:425-32 pubmed publisher
    The familial cylindromatosis tumour suppressor CYLD contains three cytoskeleton-associated protein glycine-rich (CAP-Gly) domains and a deubiquitinase domain...
  4. Jenner M, Leone P, Walker B, Ross F, Johnson D, Gonzalez D, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110:3291-300 pubmed
    ..loss of heterozygosity (LOH) involving 3 regions: the whole of 16q, a region centered on 16q12 (the location of CYLD), and a region centered on 16q23 (the location of the WW domain-containing oxidoreductase gene WWOX)...
  5. Alameda J, Moreno Maldonado R, Navarro M, Bravo A, Ramirez A, Page A, et al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene. 2010;29:6522-32 pubmed publisher
    In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD(C/S)) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD ..
  6. Komatsu K, Lee J, Miyata M, Hyang Lim J, Jono H, Koga T, et al. Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun. 2013;4:1684 pubmed publisher
    The deubiquitinase CYLD acts as a key negative regulator to tightly control overactive inflammation...
  7. O Donnell M, Perez Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol. 2011;13:1437-42 pubmed publisher
    ..We now identify CYLD as a substrate for caspase 8 that satisfies these criteria...
  8. Lim J, Jono H, Komatsu K, Woo C, Lee J, Miyata M, et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun. 2012;3:771 pubmed publisher
    ..Here we show that loss of deubiquitinase CYLD led to the development of lung fibrosis in mice after infection with Streptococcus pneumoniae...
  9. Wang L, Baiocchi R, Pal S, Mosialos G, Caligiuri M, SIF S. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol. 2005;25:7953-65 pubmed
    ..was associated with up-regulation of proapoptotic genes including the tumor suppressor familial cylindromatosis (CYLD), which was found to be a direct target of BAF57 as determined by chromatin immunoprecipitation analysis...
  10. Yoshida H, Jono H, Kai H, Li J. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem. 2005;280:41111-21 pubmed
    ..provided direct evidence for the negative regulation of TLR2 signaling by the tumor suppressor cylindromatosis (CYLD)...
  11. Hutti J, Shen R, Abbott D, Zhou A, Sprott K, Asara J, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009;34:461-72 pubmed publisher
    ..Of these potential substrates, serine 418 of the tumor suppressor CYLD was identified as a likely site of IKKepsilon phosphorylation...
  12. Gao J, Sun L, Huo L, Liu M, Li D, Zhou J. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood. 2010;115:4130-7 pubmed publisher
    Cylindromatosis (CYLD) is a deubiquitinase that was initially identified as a tumor suppressor and has recently been implicated in diverse normal physiologic processes...
  13. Tauriello D, Haegebarth A, Kuper I, Edelmann M, Henraat M, Canninga Van Dijk M, et al. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 2010;37:607-19 pubmed publisher
    ..Here, we identify the deubiquitinating enzyme CYLD, the familial cylindromatosis tumor suppressor gene, as a negative regulator of proximal events in Wnt/..
  14. Wright A, Reiley W, Chang M, Jin W, Lee A, Zhang M, et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell. 2007;13:705-16 pubmed
    ..Here we show that genetic deficiency of Cyld, a recently identified deubiquitinating enzyme, attenuates the early wave of germ cell apoptosis and causes ..
  15. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff A. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis. 2007;28:21-7 pubmed
    b>CYLD was originally identified as a tumor suppressor that is mutated in familial cylindromatosis. Recent studies suggested a role for CYLD in nuclear factor-kappaB (NF-kappaB) regulation...
  16. Pannem R, Dorn C, Ahlqvist K, Bosserhoff A, Hellerbrand C, Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2014;35:461-8 pubmed publisher
    ..Cylindromatosis (CYLD), a deubiquitination enzyme, is able to cleave the polyubiquitin chains from the substrate and to regulate ..
  17. Kovalenko A, Chable Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003;424:801-5 pubmed
    ..Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis, interacts with NEMO, the regulatory subunit of ..
  18. Brummelkamp T, Nijman S, Dirac A, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003;424:797-801 pubmed
    ..We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD), having no known function, enhances activation of the transcription factor NF-kappaB...
  19. Reiley W, Zhang M, Jin W, Losiewicz M, Donohue K, Norbury C, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol. 2006;7:411-7 pubmed
    ..Here we identify the deubiquitinating enzyme CYLD as a positive regulator of proximal T cell receptor signaling in thymocytes...
  20. Friedman C, O Donnell M, Legarda Addison D, Ng A, Cardenas W, Yount J, et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 2008;9:930-6 pubmed publisher
    ..Microarray and bioinformatic analysis indicated that the expression of RIG-I and that of the tumour suppressor CYLD (cylindromatosis), a deubiquitinating enzyme that removes Lys 63-linked polyubiquitin chains, are closely ..
  21. Fukuda M, Hiroi M, Suzuki S, Ohmori Y, Sakashita H. Loss of CYLD might be associated with development of salivary gland tumors. Oncol Rep. 2008;19:1421-7 pubmed
    ..skin, have demonstrated frequent alterations at chromosome 16q12-13, recently found to house the cylindromatosis (CYLD) gene...
  22. Takiuchi T, Nakagawa T, Tamiya H, Fujita H, Sasaki Y, Saeki Y, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells. 2014;19:254-72 pubmed publisher
    ..enzymes (DUBs), ovarian tumor DUB with linear linkage specificity (OTULIN/Gumby/FAM105B) and cylindromatosis (CYLD) that can cleave linear polyubiquitin chains and interact with LUBAC via the N-terminal PNGase/UBA or UBX (PUB) ..
  23. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003;424:793-6 pubmed
    ..Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function...
  24. Saggar S, Chernoff K, Lodha S, Horev L, Kohl S, Honjo R, et al. CYLD mutations in familial skin appendage tumours. J Med Genet. 2008;45:298-302 pubmed publisher
    Germ-line mutations in CYLD are found in patients with familial skin appendage tumours. The protein product functions as a deubiquitinase enzyme, which negatively regulates NF-kappaB and c-Jun N-terminal kinase signalling...
  25. Massoumi R. Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci. 2010;35:392-9 pubmed publisher
    The tumor suppressor CYLD is a deubiquitylating enzyme that negatively regulates different signaling pathways by removing lysine 63-linked polyubiquitin chains from several specific substrates...
  26. Zhang X, Liang Y, He P, Yang S, Wang H, Chen J, et al. Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma. J Invest Dermatol. 2004;122:658-64 pubmed
    ..Therefore, we speculated that the cylindromatosis gene (CYLDI gene) responsible for FC may be related to the pathogenesis of MFT...
  27. Stegmeier F, Sowa M, Nalepa G, Gygi S, Harper J, Elledge S. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A. 2007;104:8869-74 pubmed
    Mutations in the cylindromatosis (CYLD) gene cause benign tumors of skin appendages, referred to as cylindromas...
  28. Reiley W, Zhang M, Wu X, Granger E, Sun S. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol. 2005;25:3886-95 pubmed
    Tumor suppressor CYLD is a deubiquitinating enzyme (DUB) that inhibits the ubiquitination of key signaling molecules, including tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2)...
  29. Espinosa L, Cathelin S, D Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18:268-81 pubmed publisher
    ..Hes1 exerts its effects by repressing the deubiquitinase CYLD, a negative IKK complex regulator. CYLD expression was found to be significantly suppressed in primary T-ALL...
  30. Moquin D, McQuade T, Chan F. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS ONE. 2013;8:e76841 pubmed publisher
    ..Cylindromatosis (CYLD) is believed to promote programmed necrosis by facilitating RIP1 deubiquitination at this membrane receptor complex...
  31. O Donnell M, Hase H, Legarda D, Ting A. NEMO inhibits programmed necrosis in an NFκB-independent manner by restraining RIP1. PLoS ONE. 2012;7:e41238 pubmed publisher
    ..These results indicate that recruitment of NEMO to ubiquitinated RIP1 is a key step in the TNFR1 signaling pathway that determines whether RIP1 triggers a necrotic death response. ..
  32. Rajan N, Langtry J, Ashworth A, Roberts C, Chapman P, Burn J, et al. Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol. 2009;145:1277-84 pubmed publisher
    ..of clinical features in affected individuals from 2 large families with proven heterozygous mutations in the CYLD locus and to correlate these findings with the 3 appendageal tumor predisposition syndromes (familial ..
  33. Biggs P, Chapman P, Lakhani S, Burn J, Stratton M. The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene. 1996;12:1375-7 pubmed
    ..We recently localised the gene responsible for this disease (cyld1) to chromosome 16q12-q13 and provided evidence that it is a tumour suppressor gene (Biggs et al., 1995)...
  34. Komander D, Reyes Turcu F, Licchesi J, Odenwaelder P, Wilkinson K, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 2009;10:466-73 pubmed publisher
    ..All analysed DUBs, except CYLD, cleave linear chains less efficiently compared with other chain types, or not at all...
  35. Jono H, Lim J, Chen L, Xu H, Trompouki E, Pan Z, et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem. 2004;279:36171-4 pubmed
    ..Recent studies have identified the tumor suppressor CYLD, loss of which causes a benign human syndrome called cylindromatosis, as a key negative regulator for NF-kappaB ..
  36. Reiley W, Zhang M, Sun S. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem. 2004;279:55161-7 pubmed
    b>CYLD is a tumor suppressor that is mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple tumors of the skin appendages...
  37. Sakai A, Koga T, Lim J, Jono H, Harada K, Szymanski E, et al. The bacterium, nontypeable Haemophilus influenzae, enhances host antiviral response by inducing Toll-like receptor 7 expression: evidence for negative regulation of host anti-viral response by CYLD. FEBS J. 2007;274:3655-3668 pubmed publisher
    ..Interestingly, CYLD, a novel deubiquitinase, acts as a negative regulator of TLR7 induction by NTHi...
  38. Almeida S, Maillard C, Itin P, Hohl D, Huber M. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. J Invest Dermatol. 2008;128:587-93 pubmed
    ..are autosomal-dominant genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized on chromosome 16q12-q13...
  39. Komander D, Lord C, Scheel H, Swift S, Hofmann K, Ashworth A, et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell. 2008;29:451-64 pubmed publisher
    The tumor suppressor CYLD antagonizes NF-kappaB and JNK signaling by disassembly of Lys63-linked ubiquitin chains synthesized in response to cytokine stimulation...
  40. Koga T, Lim J, Jono H, Ha U, Xu H, Ishinaga H, et al. Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. J Biol Chem. 2008;283:12546-54 pubmed publisher
    ..Interestingly, we found for the first time that tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for S...
  41. Blake P, Toro J. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat. 2009;30:1025-36 pubmed publisher
    Germline mutations in the cylindromatosis (CYLD) gene have been described in families with cylindromas, trichoepitheliomas, and/or spiradenomas...
  42. Gao J, Huo L, Sun X, Liu M, Li D, Dong J, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem. 2008;283:8802-9 pubmed publisher
    The familial cylindromatosis tumor suppressor CYLD is known to contain three cytoskeleton-associated protein glycine-rich (CAP-Gly) domains, which exist in a number of microtubule-binding proteins and are responsible for their association ..
  43. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125:665-77 pubmed
    Mutations in the CYLD gene cause tumors of hair-follicle keratinocytes. The CYLD gene encodes a deubiquitinase that removes lysine 63-linked ubiquitin chains from TRAF2 and inhibits p65/p50 NF-kappaB activation...
  44. Liu P, Xu B, Shen W, Zhu H, Wu W, Fu Y, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012;26:1293-300 pubmed publisher
    ..Two core components of necroptotic machine, RIP3 and deubiquitinase cylindromatosis (CYLD), are markedly downregulated in CLL...
  45. Stokes A, Wakano C, Koblan Huberson M, Adra C, Fleig A, Turner H. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal. 2006;18:1584-94 pubmed
    ..We describe that TRPA1 associates with the tumor-suppressor protein CYLD. TRPA1 is a novel substrate for the de-ubiquitinating activity of CYLD, and this de-ubiquitination has the net ..
  46. Lim J, Jono H, Koga T, Woo C, Ishinaga H, Bourne P, et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS ONE. 2007;2:e1032 pubmed
    ..The deubiquitinating enzyme cylindromatosis (CYLD), loss of which was originally reported to cause a benign human syndrome called cylindromatosis, has been ..
  47. Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. Structure. 2004;12:1719-28 pubmed
    b>CYLD was originally identified as the human familial cylindromatosis tumor suppressor. Recently, it was reported that CYLD directly interacts with NEMO/IKKgamma and TRAF2 in the NF-kappaB signaling pathway...
  48. Regamey A, Hohl D, Liu J, Roger T, Kogerman P, Toftgard R, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med. 2003;198:1959-64 pubmed
    Cylindromas are benign adnexal skin tumors caused by germline mutations in the CYLD gene. In most cases the second wild-type allele is lost in tumor tissue, suggesting that CYLD functions as tumor suppressor...
  49. Bignell G, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000;25:160-5 pubmed
    ..The susceptibility gene (CYLD) has previously been localized to chromosome 16q and has the genetic attributes of a tumour-suppressor gene (..
  50. Kang S, Yu T, Liu T, Guan S. Eco-friendly preparation of large-sized graphene via short-circuit discharge of lithium primary battery. J Colloid Interface Sci. 2017;512:489-496 pubmed publisher
    ..The gained graphene is characterized by Raman spectrum, X-ray diffraction (XRD), transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), Atomic force microscope (AFM) and Scanning electron microscopy (SEM)...
  51. Ishwarya R, Vaseeharan B, Kalyani S, Banumathi B, Govindarajan M, Alharbi N, et al. Facile green synthesis of zinc oxide nanoparticles using Ulva lactuca seaweed extract and evaluation of their photocatalytic, antibiofilm and insecticidal activity. J Photochem Photobiol B. 2018;178:249-258 pubmed publisher
    ..FTIR) spectroscopy, selected area electron diffraction (SAED) analysis and transmission electron microscopy (TEM). The U...
  52. Ghaznavi H, Hosseini Nami S, Kamrava S, Irajirad R, Maleki S, Shakeri Zadeh A, et al. Folic acid conjugated PEG coated gold-iron oxide core-shell nanocomplex as a potential agent for targeted photothermal therapy of cancer. Artif Cells Nanomed Biotechnol. 2017;:1-11 pubmed publisher
    ..The synthesized nanocomplex was characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), UV-Vis spectroscopy, vibrating sample magnetometry (VSM), and Fourier transform ..
  53. Chen J, Li X, Sun Y, Hu Y, Peng Y, Li Y, et al. Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents. Chemistry. 2017;23:17279-17289 pubmed publisher
    ..The nanoparticles were characterized by TEM and dynamic light scattering...
  54. Nishimura T, Raman V. Corrosion Prevention of Aluminum Nanoparticles by a Polyurethane Coating. Materials (Basel). 2014;7:4710-4722 pubmed publisher
    ..The surface of the polymer coating was investigated by Transmission Electron Microscopy (TEM) and Atomic Force Microscopy (AFM), and the corrosion resistance of the nanoparticles was estimated by a wet/dry ..
  55. Murugan K, Choonara Y, Kumar P, du Toit L, Pillay V. Neo-Geometric Copper Nanocrystals by Competitive, Dual Surfactant-Mediated Facet Adsorption Controlling Skin Permeation. Materials (Basel). 2016;9: pubmed publisher
    ..surfactant coat and the synthesis of a novel copper-polymer complex and extensive transmission electron microscopy (TEM) was conducted to determine the nanoparticle morphology...
  56. Yang Y, Yang Y, Lei C, Liu B, Jiang W, Wang H, et al. Characterization of pHeBE7, an IncFII-type virulence-resistance plasmid carrying blaCTX-M-98b, blaTEM-1, and rmtB genes, detected in Escherichia coli from a chicken isolate in China. Plasmid. 2017;92:37-42 pubmed publisher
    ..we sequenced the complete pHeBE7 plasmid, an 86,015-bp plasmid that contains the blaCTX-M-98b, blaTEM-1, rmtB, and traT genes, using whole-genome sequencing...
  57. Du G, Yang N, Gong W, Fang Y, He J, Zhou N, et al. CD8+ effector memory T cells induce acute rejection of allogeneic heart retransplants in mice possibly through activating expression of inflammatory cytokines. Exp Cell Res. 2017;355:1-8 pubmed publisher
    To investigate the effects of CD8+ memory T (Tm) cells and CD8+ effector memory T (Tem) cells on the results of allogeneic heart retransplantations performed in mice...
  58. Khachatryan G, Khachatryan K, Grzyb J, Fiedorowicz M. Formation and properties of hyaluronan/nano Ag and hyaluronan-lecithin/nano Ag films. Carbohydr Polym. 2016;151:452-7 pubmed publisher
    ..The dry foils were stored in a closed container. UV-vis spectroscopy, transmission electron microscopy (TEM) and Fourier transform infrared (FTIR) spectra confirmed formation of about 10nm ball-shaped Ag nanoparticles ..
  59. Park E, Gleghorn M, Maquat L. Staufen2 functions in Staufen1-mediated mRNA decay by binding to itself and its paralog and promoting UPF1 helicase but not ATPase activity. Proc Natl Acad Sci U S A. 2013;110:405-12 pubmed publisher
    ..SMD) is a posttranscriptional regulatory mechanism in mammals that degrades mRNAs harboring a STAU1-binding site (SBS) in their 3'-untranslated regions (3' UTRs). We show that SMD involves not only STAU1 but also its paralog STAU2...
  60. Chen Y, Ding H, Sun S. Preparation and Characterization of ZnO Nanoparticles Supported on Amorphous SiO₂. Nanomaterials (Basel). 2017;7: pubmed publisher
    ..Furthermore, the SEM and TEM observations showed that ZnO nanoparticles with a particle size of 3-8 nm were uniformly and dispersedly loaded on ..
  61. Dupont H, Choinier P, Roche D, Adiba S, Sookdeb M, Branger C, et al. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..that they belonged to the ST131 clonal group, had the predicted O25b:H4 serotype, and produced the CTX-M-15 and TEM-1 β-lactamases. One nucleotide substitution was identified between these strains...
  62. Mao K, Shu W, Liu L, Gu Q, Qiu Q, Wu X. Salvianolic Acid A Inhibits OX-LDL Effects on Exacerbating Choroidal Neovascularization via Downregulating CYLD. Oxid Med Cell Longev. 2017;2017:6210694 pubmed publisher
    ..However, its role in CNV progression remained unclear. Salvianolic acid A is widely used in vascular diseases. We investigated the relationship between OX-LDL and CNV and explore antineovascularization mechanism of Sal A...